Quotient Sciences Wins Multiple Categories in 2023 CDMO Leadership Awards
Quotient Sciences is a multi-category award winner of the 2023 CDMO Leadership Awards. Now in its 12th year, the CDMO Leadership Awards recognizes superior performance by contract development and manufacturing organizations (CDMO's) across multiple categories, as voted by customers.
HPAPI supply chain: Why manufacturers should care about handling and transportation
An increasing number of drug development pipelines are turning towards the use of HPAPIs to target rare and 'undruggable' diseases. Speaking with CPHI Online, Quotient Sciences share their thoughts on the HPAPI supply chain, manufacturing and handling considerations.
Quotient Sciences Expands Formulation Development Capabilities at Nottingham, UK
An expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.
Stuart McDougall: European Bioanalysis Forum Workshop Contribution
Stuart McDougall, Quotient Sciences' Principal Research Fellow of Bioanalytical Services, contributes to the European Bioanalysis Forum Workshop on the Harmonized Implementation of the ICH M10 Guideline.
Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study
Ensysce Biosciences' PF614-MPAR, could be the industry's first overdose protection pain product, now entering a final Phase 1 study with Quotient Sciences.